Teresa Ho, PharmD
Teresa Ho, PharmD
Program: Precision Medicine
Language(s): English
-
Publications
- Ho TT, Smith DM, Aquilante CL, Cicali EJ, El Rouby N, Hertz DL, Imanirad I, Patel JN, Scott SA, Swain SM, Tuteja S, Hicks JK. A Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines into Clinical Practice. Clin Pharmacol Ther. 2025 May.117(5):1194-1208. Pubmedid: 39887719. Pmcid: PMC11993294.
- Cavallari LH, Hicks JK, Patel JN, Elchynski AL, Smith DM, Bargal SA, Fleck A, Aquilante CL, Killam SR, Lemke L, Ochi T, Ramsey LB, Haidar CE, Ho T, El Rouby N, Monte AA, Allen JD, Beitelshees AL, Bishop JR, Bousman C, Campbell R, Cicali EJ, Cook KJ, Duong B, Tsermpini EE, Girdwood ST, Gregornik DB, Grimsrud KN, Lamb N, Lee JC, Lopez RO, Mazhindu TA, Morris SA, Nagy M, Nguyen J, Pasternak AL, Petry N, van Schaik RHN, Schultz A, Skaar TC, Al Alshaykh H, Stevenson JM, Stone RM, Tran NK, Tuteja S, Woodahl EL, Yuan LC, Lee CR. The Pharmacogenomics Global Research Network Implementation Working Group: global collaboration to advance pharmacogenetic implementation. Pharmacogenet Genomics. 2025 Jan.35(1):1-11. Pubmedid: 39485373. Pmcid: PMC11664750.
- Miao R, Blue K, Sommerer K, Shah A, Bottiglieri S, Del Cueto A, Berry DK, Ho TT, Hicks JK, Kim DW. PARP Inhibitors in Pancreatic Cancer with Homologous Recombination Repair Gene Mutations: A Single-Institution Experience. Cancers (Basel). 2024 Oct.16(20). Pubmedid: 39456541. Pmcid: PMC11505755.
- Tracksdorf T, Smith DM, Pearse S, Cicali EJ, Aquilante CL, Scott SA, Ho TT, Patel JN, Hicks JK, Hertz DL. Strategies for DPYD testing prior to fluoropyrimidine chemotherapy in the US. Support Care Cancer. 2024 Jul.32(8):497. Pubmedid: 38980476.
- Ho TT, Perkins JB, Gonzalez R, Hicks JK, Martinez RA, Duranceau K, North B, Kim J, Teer JK, Yao J, Yoder SJ, Nishihori T, Bejanyan N, Pidala J, Elmariah H. Association between CYP3A4, CYP3A5 and ABCB1 genotype and tacrolimus treatment outcomes among allogeneic HSCT patients. Pharmacogenomics. 2024 Jan.25(1):29-40. Pubmedid: 38189154.
- Ho TT, Noble M, Tran BA, Sunjic K, Gupta SV, Turgeon J, Crutchley RD. Clinical Impact of the CYP2C19 Gene on Diazepam for the Management of Alcohol Withdrawal Syndrome. J Pers Med. 2023 Feb.13(2). Pubmedid: 36836519. Pmcid: PMC9961427.
- Ho TT, Bell G, Gammal RS, Gregornik D, Wake DT, Dunnenberger HM. A clinician's guide for counseling patients on results of a multigene pharmacogenomic panel. Am J Health Syst Pharm. 2022 Sep.79(19):1634-1644. Pubmedid: 35876085.
- Smith DM, Stevenson JM, Ho TT, Formea CM, Gammal RS, Cavallari LH. Pharmacogenetics: A Precision Medicine Approach to Combatting the Opioid Epidemic. J Am Coll Clin Pharm. 2022 Feb.5(2):239-250. Pubmedid: 35784584. Pmcid: PMC9248444.
- Wake DT, Bell GC, Gregornik DB, Ho TT, Dunnenberger HM. Synthesis of major pharmacogenomics pretest counseling themes: a multisite comparison. Pharmacogenomics. 2021 Feb.22(3):165-176. Pubmedid: 33461326.
- Gonsalves SG, Dirksen RT, Sangkuhl K, Pulk R, Alvarellos M, Vo T, Hikino K, Roden D, Klein T, Mark Poler S, Patel S, Caudle KE, Gordon R, Brandom B, Biesecker LG. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR1 or CACNA1S Genotypes. Clin Pharmacol Ther. 2019 Jun.105(6):1338-1344. Pubmedid: 30499100. Pmcid: PMC6513720.
- Tran AX, Ho TT, Varghese Gupta S. Role of CYP2B6 pharmacogenomics in bupropion-mediated smoking cessation. J Clin Pharm Ther. 2019 Apr.44(2):174-179. Pubmedid: 30578565.
- Weitzel KW, Smith DM, Elsey AR, Duong BQ, Burkley B, Clare-Salzler M, Gong Y, Higgins TA, Kong B, Langaee T, McDonough CW, Staley BJ, Vo TT, Wake DT, Cavallari LH, Johnson JA. Implementation of Standardized Clinical Processes for TPMT Testing in a Diverse Multidisciplinary Population: Challenges and Lessons Learned. Clin Transl Sci. 2018 Mar.11(2):175-181. Pubmedid: 29351371. Pmcid: PMC5867028.
- Patel RV, Chudow M, Vo TT, Serag-Bolos ES. Evaluation of pharmacy students' knowledge and perceptions of pharmacogenetics before and after a simulation activity. Curr Pharm Teach Learn. 2018 Aug.10(1):96-101. Pubmedid: 29248082.
- Vo TT, Bell GC, Owusu Obeng A, Hicks JK, Dunnenberger HM. Pharmacogenomics Implementation: Considerations for Selecting a Reference Laboratory. Pharmacotherapy. 2017 Sep.37(9):1014-1022. Pubmedid: 28699700.
- Knepper TC, Bell GC, Hicks JK, Padron E, Teer JK, Vo TT, Gillis NK, Mason NT, McLeod HL, Walko CM. Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience. Oncologist. 2017 Feb.22(2):144-151. Pubmedid: 28179575. Pmcid: PMC5330702.
- Brinda BJ, Viganego F, Vo T, Dolan D, Fradley MG. Anti-VEGF-Induced Hypertension: a Review of Pathophysiology and Treatment Options. Curr Treat Options Cardiovasc Med. 2016 May.18(5):33. Pubmedid: 26932588.
- Vo TT, Varghese Gupta S. Role of Cytochrome P450 2B6 Pharmacogenomics in Determining Efavirenz-Mediated Central Nervous System Toxicity, Treatment Outcomes, and Dosage Adjustments in Patients with Human Immunodeficiency Virus Infection. Pharmacotherapy. 2016 Dec.36(12):1245-1254. Pubmedid: 27779789.
- Karnes JH, McDonough CW, Gong Y, Vo TT, Langaee TY, Chapman AB, Gums JG, Beitelshees AL, Bailey KR, Del-Aguila JL, Boerwinkle EA, Pepine CJ, Turner ST, Johnson JA, Cooper-DeHoff RM. Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment. Pharmacogenomics J. 2013 Oct.13(5):430-436. Pubmedid: 22907731. Pmcid: PMC3529742.
-
Patient Comments
0 patients rated this provider
The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.
Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Learn more about our patient satisfaction surveyComments
Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.
Learn more about our patient comments
We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.
Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:
Learn more about our patient satisfaction survey, ratings and comments